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Abstract
Background—Concerns remain regarding the cancer risk associated with perinatal antiretroviral 
(ARV) exposure among infants. No excessive cancer risk has been found in short-term studies.
Methods—Children born to HIV-infected women (HIV-exposed) in New Jersey from 1995 to 
2008 were identified through the Enhanced HIV/AIDS Reporting System and cross-referenced 
with data from the New Jersey State Cancer Registry to identify new cases of cancer among 
children who were perinatally exposed to ARV. Matching of individuals in the Enhanced HIV/
AIDS Reporting System to the New Jersey State Cancer Registry was conducted based on name, 
birth date, Social Security number, residential address, and sex using AutoMatch. Age- and sex-
standardized incidence ratio (SIR) and exact 95% confidence intervals (CIs) were calculated using 
New Jersey (1979–2005) and US (1999–2009) cancer rates.
Results—Among 3087 children (29,099 person-years; median follow-up: 9.8 years), 4 were 
diagnosed with cancer. Cancer incidence among HIV-exposed children who were not exposed to 
ARV prophylaxis (22.5 per 100,000 person-years) did not differ significantly from the incidence 
among children who were exposed to any perinatal ARV prophylaxis (14.3 per 100,000 person-
years). Furthermore, the number of cases observed among individuals exposed to ARV did not 
differ significantly from cases expected based on state (SIR = 1.21; 95% CI: 0.25 to 3.54) and 
national (SIR = 1.27; 95% CI: 0.26 to 3.70) reference rates.
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Conclusions—Our findings are reassuring that current use of ARV for perinatal HIV 
prophylaxis does not increase cancer risk. We found no evidence to alter the current federal 
guidelines of 2014 that recommend ARV prophylaxis of HIV-exposed infants.
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INTRODUCTION
Antiretroviral (ARV) prophylaxis for prevention of mother-to-child HIV transmission was 
recommended by the US Public Health Service for all HIV-infected pregnant women and 
their infants in 1994.1 Initially, the regimen for the woman and the infant included only 
zidovudine, a nucleoside reverse-transcriptase inhibitor (NRTI), but by the late 1990s, 
combination ARV therapy during pregnancy was recommended for women.2 Between 1994 
and 2010, approximately 100,000 US infants were prenatally exposed to ARV; in the same 
time frame, it is estimated that more than 25,000 cases of perinatally acquired HIV infection 
were prevented that would have occurred in the absence of ARV prophylaxis.3
NRTIs are usually important components of ARV prophylaxis regimens. NRTI binds nuclear 
and mitochondrial DNA and thus inhibits DNA polymerase-γ, which is responsible for 
mitochondrial DNA replication. Therefore, since the time of the first recommendation for 
neonatal prophylaxis, there have been concerns about short- and long-term risks of NRTI 
use. Observed adverse events have included hematologic toxicities (anemia4–9 and 
leukopenia4–6,8,10–12), which are usually transient and infrequently of clinical significance. 
Lactic acidemia, likewise transient and usually insignificant, has been reported as well.13–16 
More significant mitochondrial dysfunction was originally reported in small numbers of 
ARV exposees in France17 and was identified on the basis of symptoms in the Pediatric 
AIDS Clinical Trials Group (PACTG) 219/219C in 20 of 1037 children (prevalence 1.9%) 
born between 1991 and 2002.18 However, symptomatic mitochondrial dysfunction was not 
found to be associated with deaths of HIV-exposed uninfected children in a large 
collaborative cohort in the United States.19
Nuclear binding of NRTI has raised the possibility of cancer and remains a concern because 
of its potential occurrence over a longer time frame. There were no cases of cancer identified 
in the first years of follow-up of infant participants in PACTG 07620 or in a collaborative 
study from the Women and Infants Transmission Study and PACTG 219.21 Larger studies 
with longer follow-up of HIV-exposed, ARV-exposed HIV-uninfected children found either 
no cases of cancer22 or rates of cancer statistically indistinguishable from the rate in the 
general population.23,24 To investigate cancer risk over a longer period, we conducted a 
match between New Jersey's surveillance data among HIV-exposed, ARV-exposed children 
and the State Cancer Registry.
METHODS
Children born to HIV-infected women (HIV-exposed) in New Jersey from 1995 to 2008 
were identified through the Enhanced HIV/AIDS Reporting System and cross-referenced 
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with data from the New Jersey State Cancer Registry to identify new cases of cancer among 
children who were exposed to ARV prenatally, during birth, or postnatally. Matching was 
based on name, birth date, Social Security number, address of residence, and sex. 
AutoMatch is a commercially available software that implements probabilistic record 
linkage methodology for matching records under conditions of uncertainty.25 The resulting 
linked data set was updated with vital records from the New Jersey Office of Vital Statistics 
and Registry to determine deaths among the sample. Sample size, follow-up time, and 
cancer incidence were determined for all HIV-exposed infants, HIV-exposed infants with no 
ARV exposure, HIV-exposed infants with any ARV exposure, and HIV-exposed infants with 
prenatal ARV exposure.
A child exposed to ARV at any stage was considered “exposed,” while “no exposure” was 
recorded if “no” was indicated for all questions in the Enhanced HIV/AIDS Reporting 
System that indicated ARV receipt. Follow-up was censored at cancer diagnosis, death, or 
end of the study on December 31, 2010. Age- and sex-standardized incidence ratio (SIR) 
was calculated by comparing observed cases with expected cases. Expected cases were 
calculated using the method described by Scklo and Nieto26 and performed separately based 
on New Jersey cancer rates between 1979 and 200527 and US cancer rates between 1999 and 
2009.28 Exact confidence intervals (CIs) for SIR were calculated directly from the Poisson 
distribution29–31 using an alpha of 0.05. Chi-square was used to test associations between 
demographic variables and ARV receipt. HIV-infected children were excluded from the 
analysis because of the known risk of cancer associated with HIV infection.
This analysis was approved by the Institutional Review Board of the University of Medicine 
and Dentistry of New Jersey and given a nonresearch determination for purposes of internal 
review by the Human Protections Administrator of the New Jersey Department of Health 
and Senior Services.
RESULTS
Between 1995 and 2008, 3421 children were born to HIV-infected women in New Jersey. Of 
these perinatally HIV-exposed children, 90% were not infected with HIV, resulting in 3085 
exposed uninfected children. Of the 2721 (88%) children with information on ARV 
exposure, 2326 (85%) received ARV prophylaxis to prevent the establishment of HIV 
infection. Among these 2326 children, 81% received ARV prophylaxis prenatally, 81% 
during birth, and 98% postnatally (Fig. 1). Follow-up time for all HIV-exposed uninfected 
children totaled 29,099 person-years; median follow-up time per child was 9.8 years (range: 
<1 to 16 years).
Perinatally HIV-exposed uninfected children were evenly distributed across sex categories 
with 52% being male (Table 1). The majority of children were non-Hispanic black (69%), 
followed by Hispanic (19%), and non-Hispanic white (10%). Seventy-three percent of 
children were delivered at full term. As of December 31, 2010, 54 children (2%) had been 
reported to the New Jersey Office of Vital Statistics and Registry as deceased. A smaller 
proportion of non-Hispanic blacks were perinatally exposed to ARV (84%) than children of 
other races/ethnicities (range: 88%–90%). Those who had been reported to the State as 
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deceased had a significantly lower proportion of ARV exposure than those who were not 
reported as deceased (70% vs. 86%; P = 0.0015).
Among the 3085 perinatally HIV-exposed uninfected children born between 1995 and 2008, 
4 were diagnosed with cancer (Hodgkin nodular sclerosis, acute myeloid leukemia, 
hepatocellular carcinoma, and pleuropulmonary blastoma) (Table 2). Three of the diagnoses 
(75%) were among males, and all diagnoses were among non-Hispanic blacks. Three of the 
4 children with cancer diagnoses were exposed to ARV prophylaxis at some point before, 
during, or after birth. The age at cancer diagnosis ranged from <1 to 7 years.
The incidence of all cancer types identified among all HIV-exposed uninfected children was 
13.7 per 100,000 person-years (95% CI: 3.7 to 35.2). Cancer incidence among HIV-exposed 
children who were not exposed to ARV prophylaxis [22.5 per 100,000 person-years (95% 
CI: 0.6 to 125.3)] did not differ significantly from the incidence among children who were 
exposed to any ARV prophylaxis [14.3 per 100,000 person-years (95% CI: 3.0 to 41.9)] or 
who were exposed to ARV prophylaxis prenatally [18.1 per 100,000 person-years (95% CI: 
3.7 to 52.7)], during birth [12.3 per 100,000 person-years (95% CI: 1.5 to 44.3)], or 
postnatally [14.7 per 100,000 person-years (95% CI: 3.0 to 42.8)] (Table 3).
The number of cases observed among individuals exposed to ARV at any time did not differ 
significantly from cases expected based on state (SIR = 1.21; 95% CI: 0.25 to 3.54) and 
national (SIR = 1.27; 95% CI: 0.26 to 3.70) reference rates. Furthermore, the observed 
number of cancer cases among those exposed to ARV prophylaxis at each stage, prenatal, 
intrapartum, and postnatal, did not differ significantly from cases expected based on state 
and national rates (Table 4).
DISCUSSION
In this investigation, 16 years of cancer registry and HIV case surveillance data were 
reviewed to assess the risk of cancer among HIV-exposed uninfected children who were 
perinatally exposed to ARV prophylaxis. This study period represents the longest median 
follow-up time of any cancer study among HIV-exposed uninfected children and is the 
second largest in terms of total follow-up. No elevated cancer risk was found among children 
who were exposed to ARV prophylaxis at each or any time before, during, or after birth, 
when compared with HIV-exposed children who were not perinatally exposed to ARV 
prophylaxis. Moreover, the number of cases observed in this investigation among those who 
were exposed to ARV prophylaxis at each or any time before, during, or after birth did not 
differ from state or national cancer incidence rates of children aged from <1 to 19 years.
The results of this study are consistent with those of previous research. The incidence of 
cancer in HIV-exposed uninfected children is comparable with that in the French National 
Perinatal Study (18.8/100,000 person-years)23 and in PACTG 219C in the United States 
(12.7/100,000 person-years).24 These 2 studies, respectively, followed study participants for 
53,052 person-years (median: 5.4 years/person) and 7871 person-years (median: 3.1 years/
person). Furthermore, earlier studies in the United States, a follow-up study of PACTG 076 
(median follow-up: 4.2 years/person)20 and a collaborative study including data from the 
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Women and Infants Transmission Study and PACTG 219 (follow-up: 14.5 and 38.3 months/
person, respectively, and total follow-up of 1111 person-years),21 found no cancers. 
Likewise, a study in the United Kingdom that linked data from the National Study of HIV in 
Pregnancy and Childhood to records of the National Health Service found no cases over a 
period of 7013 person-years (median: 2.5 years/person, range: 1.0–5.0).22
There are limitations in this study that should be considered when interpreting these 
findings. Data on ARV exposure were incomplete; of the perinatally HIV-exposed 
uninfected children, 12% were missing information on ARV exposure. The effect of these 
missing data on our findings is unknown. However, those with missing ARV information 
were not different from those with ARV information with respect to cancer diagnosis, death, 
sex, or race. Second, cancer diagnoses and deaths that occurred outside New Jersey, or were 
not recorded in state records, were not identified in our analyses. Therefore, we cannot 
quantify loss to follow-up of individuals who moved or sought care outside New Jersey, 
which could have resulted in an underestimate of incidence. Furthermore, data on the exact 
timing and duration of intrauterine exposure to ARV were not available; thus, we were 
unable to quantify a child's exposure to ARV. Finally, this is an investigation of HIV-exposed 
children born in the state of New Jersey, thus, these findings should not be generalized 
beyond this population.
The reduction of mother-to-child transmission of HIV in the United States is a major public 
health success, and ARV prophylaxis is an integral part of the mother-to-child transmission 
prevention cascade.32 Cancer incidence in HIV-exposed but uninfected ARV-exposed 
children was not significantly different from incidence in the general population of children 
and adolescents less than 19 years of age. However, because of the evolving spectrum of 
ARV usage by pregnant women, further monitoring of the risk of cancer and of other health 
outcomes associated with ARV exposure is needed to ensure that ARV medications are safe 
for mothers and children. Our data are reassuring that current use of ARV for perinatal 
prophylaxis does not increase cancer risk. We found no evidence to alter the current federal 
guidelines of 2014 that recommend ARV prophylaxis of HIV-exposed infants.33
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FIGURE 1. 
Flowchart of study sample and ARV exposure type.
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TABLE 1
Characteristics of Perinatally HIV-Exposed Uninfected Children by Any ARV Prophylaxis Exposure, New 
Jersey, 1995–2008
Total Any ARV Exposure
Variable n Col, % n Row, % P *
Total 2721 100 2326 86 —
Cancer diagnosis
 Yes 4 <1 3 75 0.5514
 No 2717 >99 2323 86 —
Sex
 Male 1413 52 1202 85 0.5220
 Female 1308 48 1124 86 —
Race
 Non-Hispanic black 1876 69 1574 84 0.0057
 Non-Hispanic white 281 10 253 90 —
 Hispanic, all races 517 19 457 88 —
 Other 47 2 42 89 —
Neonatal status
 Full term 1938 73 1675 86 0.0975
 Premature† 718 27 603 84 —
Vital status (as of December 31, 2010)
 Dead 54 2 38 70 0.0015
 Alive 2667 98 2288 86 —
*Chi-square for any ARV exposure.
†
Less than 37 weeks' gestation.
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TABLE 3
Cancer Incidence Rate Among HIV-Exposed Children by ARV Exposure Type, New Jersey, 1995–2010
Cancer, n Exposed, n Follow-up Time, person-years Incidence* LL† UL†
All HIV-exposed 4 3085 29,099 13.7 3.7 35.2
 HlV-exposed, no ARV exposure 1 395 4444 22.5 0.6 125.3
 HIV-exposed, any perinatal ARV exposure 3 2326 20,909 14.3 3.0 41.9
  HIV-exposed, prenatal ARV exposure 3 1873 16,610 18.1 3.7 52.7
  HIV-exposed, intrapartum ARV exposure 2 1876 16,308 12.3 1.5 44.3
  HIV-exposed, postnatal ARV exposure 3 2283 20,464 14.7 3.0 42.8
LL, lower limit; UL, upper limit.
*
Per 100,000 person-years.
†95% CI.
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TABLE 4
SIRs for Cancer Diagnosed Among HIV-Exposed Uninfected Children, New Jersey, 1995–2010
Exposure Type Observed Cases Expected Cases (State Reference)* SIR† LI‡ UL‡
Any ARV exposure 3 2.5 1.21 0.25 3.54
 Prenatal ARV exposure 3 3.1 0.96 0.20 2.81
 Intrapartum ARV exposure 2 2.4 0.83 0.10 2.99
 Postnatal ARV exposure 3 3.0 0.99 0.20 2.88
Exposure Type Observed Cases Expected Cases (National Reference)§ SIR† LL‡ UL‡
Any ARV exposure 3 2.4 1.27 0.26 3.70
 Prenatal ARV exposure 3 3.0 1.01 0.21 2.94
 Intrapartum ARV exposure 2 2.3 0.87 0.10 3.13
 Postnatal ARV exposure 3 2.9 1.03 0.21 3.01
LL, lower limit; UL, upper limit.
*
Expected cases determined based on New Jersey cancer rates among children <19 years of age from 1979 to 2005.
†Standardized incidence rate (age and sex standardization).
‡95% CI.
§
Expected cases determined based on US cancer rates among children <19 years of age from 1999 to 2009.
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